STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.

about

STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.

Item

http://www.wikidata.org/entity/Q48275752

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

STEIN: A simple toxicity and e ...... ss phase I/II clinical trials.

@en

STEIN: A simple toxicity and e ...... ss phase I/II clinical trials.

@nl

type

Item

label

STEIN: A simple toxicity and e ...... ss phase I/II clinical trials.

@en

STEIN: A simple toxicity and e ...... ss phase I/II clinical trials.

@nl

prefLabel

STEIN: A simple toxicity and e ...... ss phase I/II clinical trials.

@en

STEIN: A simple toxicity and e ...... ss phase I/II clinical trials.

@nl

P1476

STEIN: A simple toxicity and e ...... ess phase I/II clinical trials

@en

P2093

Guosheng Yin

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials

Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.

Early phase trial design for assessing several dose levels for toxicity and efficacy for targeted agents.

A robust Bayesian dose-finding design for phase I/II clinical trials.

Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

P304

4106-4120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/SIM.7428

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ruitao Lin

P577

2017-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28786138

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

phase II clinical trial